Breaking News Instant updates and real-time market news.

ZNGA

Zynga

$4.28

0.11 (2.64%)

, BSX

Boston Scientific

$26.39

-2.12 (-7.44%)

07:30
11/29/17
11/29
07:30
11/29/17
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Tuesday in Zynga (ZNGA), Boston Scientific (BSX), and Praxair (PX).

ZNGA

Zynga

$4.28

0.11 (2.64%)

BSX

Boston Scientific

$26.39

-2.12 (-7.44%)

PX

Praxair

$156.36

4.28 (2.81%)

  • 01

    Dec

  • 05

    Dec

  • 14

    Dec

ZNGA Zynga
$4.28

0.11 (2.64%)

11/08/17
BARD
11/08/17
NO CHANGE
Target $4
BARD
Neutral
Zynga Q3 results suggest turnaround on track, says Baird
Baird analyst Colin Sebastian noted Zynga reported solid Q3 results which were above expectations. The analyst noted engagement trends continue to benefit from investments in live services and that margins improved while costs were cut. He said M&A remained disciplined while the company strengthened its position within its genre. Sebastian maintained his Neutral rating and $4 price target on Zynga shares.
09/15/17
BARD
09/15/17
NO CHANGE
Target $4
BARD
Neutral
Zynga turnaround remains well on track, says Baird
Baird analyst Colin Sebastian hosted meetings with Zynga management, which reinforced his constructive view on the company's turnaround strategy and its progress on improving profitability through live services. The analyst said beyond its Phase 1 turnaround strategy he sees a pathway for the company to move beyond 20% EBITDA margins. Sebastian maintained his Neutral rating and $4 price target on Zynga shares.
09/08/17
GSCO
09/08/17
INITIATION
Target $3.9
GSCO
Neutral
Zynga initiated with a Neutral at Goldman Sachs
Goldman analyst Christopher Merwin initiated Zynga with a Neutral and a $3.90 price target saying the company must create a "hit" game in order to re-rate shares positively and said its difficult to predict the success of new mobile IP.
07/20/17
MSCO
07/20/17
NO CHANGE
MSCO
Overweight
Morgan Stanley bullish on Zynga
Morgan Stanley analyst Brian Nowak is bullish on Zynga and positive on the Q2 report saying he expects adjusted EBITDA of $4M, 16% above consensus, and inline revenues. He expects outperformance to be driven by opex discipline and from strong performances from CSR2 and slots. Nowak believes the Zynga's strong Q1 performance was the beginning of a multi-year turnaround driven and reiterates his Overweight rating and $4.50 price target.
BSX Boston Scientific
$26.39

-2.12 (-7.44%)

11/28/17
WELS
11/28/17
NO CHANGE
WELS
Boston Scientific weakness a buying opportunity, says Wells Fargo
11/29/17
JPMS
11/29/17
NO CHANGE
Target $31
JPMS
Overweight
Boston Scientific selloff yesterday a buying opportunity, says JPMorgan
Boston Scientific last night confirmed speculation by announcing additional delays to its Lotus transcatheter valve program, JPMorgan analyst Michael Weinstein tells investors in a research note. The good news is that the delay is internally driven, the analyst notes after speaking to management. He points out that there are no issues at this point with the European notified body or with the FDA. The issue is manufacturing, Weinstein writes. The analyst is a buyer of Boston Scientific following yesterday's selloff. Despite the Lotus delay, he still thinks the company can grow organic sales by 6% in 2018 and 7%-8% in 2019-2020. Weinstein keeps an Overweight rating on Boston Scientific with a $31 price target.
11/29/17
COWN
11/29/17
NO CHANGE
Target $32
COWN
Outperform
Boston Scientific speculation worse than actual news, says Cowen
Cowen analyst Joshua Jennings noted Boston Scientific shares were weak yesterday prior to the company announcing another setback to the timelines for the Lotus valve system's European reintroduction and U.S. approval and launch. The analyst believes the speculation prior to the release was worse than the actual announcement and he believes there will be little effect on Q4 or 2017 guidance. However, admittedly, the 2018 impact is unknown at this time. Jennings reiterated his Outperform rating and $32 price target on Boston Scientific shares.
11/28/17
WELS
11/28/17
NO CHANGE
WELS
Outperform
Amid Boston Scientific slide, Wells Fargo finds no new issues with Lotus
Wells Fargo analyst Larry Biegelsen notes that weakness in shares of Boston Scientific followed the company having canceled an investor conference appearance, pointing out that the last time this happened the company then announced a recall of its Lotus TAVR device in Europe. While he attributes the pullback to investor worries about "another shoe to drop," his checks have found no new issues with Lotus, Biegelsen tells investors. Even assuming Lotus revenues were completely removed, he sees a floor for Boston Scientific at $26-$27 per share. Biegelsen maintains an Outperform rating on Boston Scientific, which is down nearly 6% to $26.86 in afternoon trading.
PX Praxair
$156.36

4.28 (2.81%)

11/13/17
ARGS
11/13/17
UPGRADE
Target $171
ARGS
Buy
Praxair upgraded to Buy at Argus on positive impact of Linde merger
As reported earlier, Argus analyst Bill Selesky upgraded Praxair to Buy from Hold with a $171 price target. Selesky says the company is well positioned to deliver stronger EPS growth thanks to its mix of high-growth businesses driving above-industry-average margins, earnings, and returns on invested capital. The analyst adds that Praxair's strategic merger with Linde AG will allow for much greater scale and geographic reach.
11/13/17
11/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. J.M. Smucker (SJM) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic saying he believes the rout of food stocks is ebbing and since this company is the worst performing stock in his coverage universe, he chose to play the food trade with it. 2. Delek US (DK) upgraded to Strong Buy from Outperform at Raymond James with analyst Justin Jenkins saying it will benefit from a wider Brent-WTI spread. 3. Nvidia (NVDA) upgraded to Market Perform from Underperform at BMO Capital with analyst Ambrish Srivastava saying the company has demonstrated a "far stronger" data center business than he had forecast and its leverage is greater than anticipated. 4. Praxair (PX) upgraded to Buy from Hold at Argus with analyst Bill Selesky saying the company is well positioned to deliver stronger Earnings Per Share growth thanks to its mix of high-growth businesses driving above-industry-average margins, earnings, and returns on invested capital. 5. TD Ameritrade (AMTD) upgraded to Buy from Hold at Deutsche Bank with analyst Brian Bedell saying trading volumes are improving, trade pricing will hold up better than expected and the Scottrade integration is going very well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/17/17
JPMS
11/17/17
NO CHANGE
Target $172
JPMS
Overweight
Praxair price target raised to $172 from $156 at JPMorgan
JPMorgan analyst Jeffrey Zekauskas raised his price target for Praxair (PX) to $172 and keeps an Overweight rating on the name. The analyst estimates the combined Praxair/Linde company is currently being valued at $145 per share. Should Praxair trade at parity to Air Products (APD), the new Praxair would be worth $172 per share, Zekauskas tells investors in a research note. He believes, however, that Praxair is capable of trading at a one multiple point premium to Air Products, which he thinks could yield a higher $189 per share value.
11/13/17
ARGS
11/13/17
UPGRADE
ARGS
Buy
Praxair upgraded to Buy from Hold at Argus

TODAY'S FREE FLY STORIES

LPSN

LivePerson

$11.05

-0.05 (-0.45%)

20:28
12/13/17
12/13
20:28
12/13/17
20:28
Initiation
LivePerson initiated  »

LivePerson initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HUSKF

Husky Energy

$12.42

-0.1177 (-0.94%)

20:26
12/13/17
12/13
20:26
12/13/17
20:26
Upgrade
Husky Energy rating change  »

Husky Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$51.68

-0.28 (-0.54%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Upgrade
ConocoPhillips rating change  »

ConocoPhillips upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

SAFM

Sanderson Farms

$167.64

0.64 (0.38%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DB

Deutsche Bank

$19.33

-0.05 (-0.26%)

19:17
12/13/17
12/13
19:17
12/13/17
19:17
Hot Stocks
DBNY, DBTCA raise prime lending rate to 4.5% from 4.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.04

-0.06 (-0.16%)

18:47
12/13/17
12/13
18:47
12/13/17
18:47
Hot Stocks
AT&T and Communications Workers of America reach tentative agreement »

AT&T Mobility has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$63.47

0.19 (0.30%)

18:33
12/13/17
12/13
18:33
12/13/17
18:33
Hot Stocks
Bristol-Myers granted exclusive license by Ono Pharma to develop ONO-4578 »

Bristol-Myers and Ono…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 05

    Mar

WFC

Wells Fargo

$59.40

-0.93 (-1.54%)

18:15
12/13/17
12/13
18:15
12/13/17
18:15
Hot Stocks
Breaking Hot Stocks news story on Wells Fargo »

Wells Fargo raises prime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

HBAN

Huntington Bancshares

$14.58

-0.23 (-1.55%)

18:10
12/13/17
12/13
18:10
12/13/17
18:10
Hot Stocks
Huntington Bancshares raises prime rate to 4.5% from 4.25% »

Huntington Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.10

-0.2 (-0.79%)

18:06
12/13/17
12/13
18:06
12/13/17
18:06
Hot Stocks
Breaking Hot Stocks news story on Associated Banc-Corp »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBS

UBS

$17.90

0.035 (0.20%)

18:05
12/13/17
12/13
18:05
12/13/17
18:05
Periodicals
UBS Wealth Management president Zeltner close to stepping down, Bloomberg says »

UBS Wealth Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.64

0.06 (0.16%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
Pfizer announces FDA approves IXIFI, a biosimilar to Remicade »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jan

CNP

CenterPoint Energy

$28.40

0.02 (0.07%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
CenterPoint Energy raises quarterly dividend 4% to 27.75c per share »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$11.99

-0.26 (-2.12%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Recommendations
MiMedx analyst commentary at Piper Jaffray »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CE

Celanese

$108.31

1.34 (1.25%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Celanese raises acetyl intermediates products prices »

Raises price on Vinyl…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$57.30

-1.25 (-2.13%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Western Alliance: Sarver to transition from chairman, CEO to exec chairman in Q1 »

Western Alliance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$54.60

-0.9 (-1.62%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
U.S. Bancorp raises prime lending rate to 4.50% from 4.25%, effective Dec 14 »

U.S. Bancorp last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

WBS

Webster Financial

$56.16

-0.73 (-1.28%)

18:00
12/13/17
12/13
18:00
12/13/17
18:00
Hot Stocks
Webster raises prime lending rate to 4.5% from 4.25% »

Webster Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HSBC

HSBC

$51.44

0.89 (1.76%)

17:56
12/13/17
12/13
17:56
12/13/17
17:56
Hot Stocks
Breaking Hot Stocks news story on HSBC »

HSBC raises prime,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$37.59

0.32 (0.86%)

17:47
12/13/17
12/13
17:47
12/13/17
17:47
Hot Stocks
Aqua America names CEO Christopher Franklin as board chairman »

Aqua America announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MSFT

Microsoft

$85.35

-0.23 (-0.27%)

17:38
12/13/17
12/13
17:38
12/13/17
17:38
Hot Stocks
Microsoft launches new AI-powered search features for Bing »

Microsoft announced in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

TCF

TCF Financial

$20.24

-0.16 (-0.78%)

17:36
12/13/17
12/13
17:36
12/13/17
17:36
Hot Stocks
Breaking Hot Stocks news story on TCF Financial »

TCF Financial raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$84.81

-1.06 (-1.23%)

17:34
12/13/17
12/13
17:34
12/13/17
17:34
Hot Stocks
Comerica Bank raises prime rate to 4.5% from 4.25% »

Comerica Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

CMCM

Cheetah Mobile

$11.18

-0.02 (-0.18%)

17:33
12/13/17
12/13
17:33
12/13/17
17:33
Hot Stocks
Breaking Hot Stocks news story on Cheetah Mobile »

Cheetah Mobile up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBS

UBS

$17.89

0.03 (0.17%)

17:33
12/13/17
12/13
17:33
12/13/17
17:33
Periodicals
Breaking Periodicals news story on UBS »

UBS Wealth Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.